Old Drugs, New Cures Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Old Drugs, New Cures Act (H.R. 8267) is a health-related bill introduced in the 118th Congress. The bill was referred to the Subcommittee on Health on December 17, 2024, but no summary or full text is publicly available. The bill's title suggests it may focus on repurposing existing drugs for new medical treatments or cures, but specific provisions, goals, or mechanisms are not provided in the available data.
H.R. 8267, the Old Drugs, New Cures Act, is a health policy bill with no publicly available text or summary, currently inactive after referral to a subcommittee and now expired.
- The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health.
- No official summary or full text is available, limiting detailed analysis of its content or objectives.
- The bill status is marked as Failed / Expired, indicating it did not advance through the legislative process.
['Potential beneficiaries could include patients and healthcare providers if the bill aimed to repurpose existing drugs for new treatments, but specific beneficiaries cannot be identified due to lack of text.', 'Health agencies and research organizations might have been involved if the bill included provisions for drug research or regulatory changes.']
['Without the bill text, it is unclear what implementation challenges, costs, or oversight mechanisms would apply.', 'The absence of detailed provisions prevents assessment of authority delegation or funding requirements.', 'Policy tradeoffs related to drug approval processes or healthcare impacts cannot be evaluated.']
The bill was introduced in the House and referred to the Subcommittee on Health during the 118th Congress but did not progress further and is now expired. No additional legislative history or debate records are available to provide context.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If the bill had provisions to repurpose existing drugs, it could have influenced pharmaceutical research priorities and healthcare treatment options.', 'Failure to pass may delay potential innovations in drug use or regulatory reforms related to drug approvals.']
The lack of publicly available bill text and summary limits transparency and public oversight. The bill's failure to advance beyond subcommittee referral further restricts opportunities for legislative scrutiny or stakeholder engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.